Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 3
2006 2
2007 4
2008 7
2009 6
2010 3
2011 5
2012 8
2013 10
2014 10
2015 11
2016 6
2017 13
2018 8
2019 7
2020 5
2021 13
2022 12
2023 16
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Atkins MB, et al. Among authors: tarhini aa. J Clin Oncol. 2023 Jan 10;41(2):186-197. doi: 10.1200/JCO.22.01763. Epub 2022 Sep 27. J Clin Oncol. 2023. PMID: 36166727 Free PMC article. Clinical Trial.
Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.
Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Li J, et al. Among authors: tarhini aa. Clin Cancer Res. 2022 May 13;28(10):2131-2146. doi: 10.1158/1078-0432.CCR-21-3145. Clin Cancer Res. 2022. PMID: 35247927 Free PMC article.
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. Grossmann KF, et al. Among authors: tarhini aa. Cancer Discov. 2022 Mar 1;12(3):644-653. doi: 10.1158/2159-8290.CD-21-1141. Cancer Discov. 2022. PMID: 34764195 Free PMC article. Clinical Trial.
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Menzies AM, et al. Among authors: tarhini aa. Nat Med. 2021 Feb;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. Nat Med. 2021. PMID: 33558722
Immunotherapy of Melanoma.
Tarhini AA. Tarhini AA. Curr Mol Pharmacol. 2016;9(3):196-207. doi: 10.2174/1874467208666150716120238. Curr Mol Pharmacol. 2016. PMID: 26177647 Review.
Adjuvant Therapy of Melanoma.
Tarhini AA. Tarhini AA. Hematol Oncol Clin North Am. 2021 Feb;35(1):73-84. doi: 10.1016/j.hoc.2020.08.012. Epub 2020 Oct 26. Hematol Oncol Clin North Am. 2021. PMID: 33759774 Review.
Neoadjuvant Therapy in Melanoma: Where Are We Now?
Saad M, Tarhini AA. Saad M, et al. Among authors: tarhini aa. Curr Oncol Rep. 2023 Apr;25(4):325-339. doi: 10.1007/s11912-023-01369-6. Epub 2023 Feb 13. Curr Oncol Rep. 2023. PMID: 36781621 Review.
Adjuvant Therapy for Melanoma.
Agha A, Tarhini AA. Agha A, et al. Among authors: tarhini aa. Curr Oncol Rep. 2017 May;19(5):36. doi: 10.1007/s11912-017-0594-5. Curr Oncol Rep. 2017. PMID: 28417343 Review.
Systemic adjuvant therapy for high-risk cutaneous melanoma.
Kobeissi I, Tarhini AA. Kobeissi I, et al. Among authors: tarhini aa. Ther Adv Med Oncol. 2022 Oct 28;14:17588359221134087. doi: 10.1177/17588359221134087. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36324735 Free PMC article. Review.
Neoadjuvant therapy of locally/regionally advanced melanoma.
Khunger A, Buchwald ZS, Lowe M, Khan MK, Delman KA, Tarhini AA. Khunger A, et al. Among authors: tarhini aa. Ther Adv Med Oncol. 2019 Jul 31;11:1758835919866959. doi: 10.1177/1758835919866959. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31391869 Free PMC article. Review.
139 results